Literature DB >> 33829337

Epstein-Barr Virus-Negative Granulomatous Disease Due to SAP Deficiency.

Takao Karasawa1, Ko Kudo1, Kay Tanita2, Yoshihiro Takahashi3, Hirokazu Kanegane4, Kiminori Terui5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33829337     DOI： 10.1007/s10875-021-01032-4

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


× No keyword cloud information.
  6 in total

1.  X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease.

Authors:  Claire Booth; Kimberly C Gilmour; Paul Veys; Andrew R Gennery; Mary A Slatter; Helen Chapel; Paul T Heath; Colin G Steward; Owen Smith; Anna O'Meara; Hilary Kerrigan; Nizar Mahlaoui; Marina Cavazzana-Calvo; Alain Fischer; Despina Moshous; Stephane Blanche; Jana Pachlopnik Schmid; Jana Pachlopnick-Schmid; Sylvain Latour; Genevieve de Saint-Basile; Michael Albert; Gundula Notheis; Nikolaus Rieber; Brigitte Strahm; Henrike Ritterbusch; Arjan Lankester; Nico G Hartwig; Isabelle Meyts; Alessandro Plebani; Annarosa Soresina; Andrea Finocchi; Claudio Pignata; Emilia Cirillo; Sonia Bonanomi; Christina Peters; Krzysztof Kalwak; Srdjan Pasic; Petr Sedlacek; Janez Jazbec; Hirokazu Kanegane; Kim E Nichols; I Celine Hanson; Neena Kapoor; Elie Haddad; Morton Cowan; Sharon Choo; Joanne Smart; Peter D Arkwright; Hubert B Gaspar
Journal:  Blood       Date:  2010-10-06       Impact factor: 22.113

2.  Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis.

Authors:  Hirokazu Kanegane; Xi Yang; Meina Zhao; Kazumi Yamato; Masami Inoue; Kazuko Hamamoto; Chie Kobayashi; Ako Hosono; Yoshikiyo Ito; Yozo Nakazawa; Kiminori Terui; Kazuhiro Kogawa; Eiichi Ishii; Ryo Sumazaki; Toshio Miyawaki
Journal:  Pediatr Allergy Immunol       Date:  2012-03-21       Impact factor: 6.377

Review 3.  Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID).

Authors:  Joon H Park; Arnold I Levinson
Journal:  Clin Immunol       Date:  2009-11-08       Impact factor: 3.969

4.  Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency.

Authors:  James W Verbsky; Mary K Hintermeyer; Pippa M Simpson; Mingen Feng; Jody Barbeau; Nagarjun Rao; Carlyne D Cool; Luis A Sosa-Lozano; Dhiraj Baruah; Erin Hammelev; Alyssa Busalacchi; Amy Rymaszewski; Jeff Woodliff; Shaoying Chen; Mary Bausch-Jurken; John M Routes
Journal:  J Allergy Clin Immunol       Date:  2020-08-01       Impact factor: 10.793

5.  Maternal onset de novo SH2D1A mutation and lymphocytic choriomeningitis virus infection in a patient with X‑linked lymphoproliferative disease type 1: a case report.

Authors:  Jinrong Liu; Wenjun Tian; Fang Wang; Wen Teng; Yang Zhang; Chunrong Tong; Chonglin Zhang; Ying Ju; Bingchang Zhang; Shunying Zhao; Hongxing Liu
Journal:  Mol Med Rep       Date:  2015-01-09       Impact factor: 2.952

6.  X-linked lymphoproliferative syndrome in mainland China: review of clinical, genetic, and immunological characteristic.

Authors:  Tao Xu; Qin Zhao; Wenyan Li; Xuemei Chen; Xiuhong Xue; Zhi Chen; Xiao Du; Xiaoming Bai; Qian Zhao; Lina Zhou; Xuemei Tang; Xi Yang; Hirokazu Kanegane; Xiaodong Zhao
Journal:  Eur J Pediatr       Date:  2019-11-21       Impact factor: 3.183
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.